Cargando…
Systemic Antifungal Therapy for Invasive Pulmonary Infections
Antifungal therapy for pulmonary fungal diseases is in a state of flux. Amphotericin B, the time-honored standard of care for many years, has been replaced by agents demonstrating superior efficacy and safety, including extended-spectrum triazoles and liposomal amphotericin B. Voriconazole, which be...
Autor principal: | Ben-Ami, Ronen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966409/ https://www.ncbi.nlm.nih.gov/pubmed/36836260 http://dx.doi.org/10.3390/jof9020144 |
Ejemplares similares
-
Treatment of Invasive Candidiasis: A Narrative Review
por: Ben-Ami, Ronen
Publicado: (2018) -
Assessment of Candida auris Response to Antifungal Drugs Using Time–Kill Assays and an Animal Model
por: Ben-Ami, Ronen, et al.
Publicado: (2017) -
Mucormycosis of the Central Nervous System
por: Chikley, Amanda, et al.
Publicado: (2019) -
Clinical Uses of Inhaled Antifungals for Invasive Pulmonary Fungal Disease: Promises and Challenges
por: Vuong, Nancy N., et al.
Publicado: (2023) -
Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies
por: Gamaletsou, Maria N., et al.
Publicado: (2018)